Human medicines European public assessment report (EPAR): Rivaroxaban Accord, rivaroxaban, Acute Coronary Syndrome;Coronary Artery Disease;Peripheral Arterial Disease;Venous Thromboembolism;Stroke;Atrial Fibrillation;Pulmonary Embolism, Date of authorisation: 16/11/2020, Revision: 5, Status: Authorised

Assessment templates and guidance

Simulect : EPAR - All Authorised presentations

Day 80 assessment report - Non-clinical template with guidance - Rev.10.23 Revamp

Day 80 assessment report - Clinical template with guidance - Rev.10.23 Revamp

Human medicines European public assessment report (EPAR): Cometriq, cabozantinib, Thyroid Neoplasms, Date of authorisation: 21/03/2014, Revision: 28, Status: Authorised

Meeting highlights from the Committee for Veterinary Medicinal Products (CVMP) 5-7 September 2023

European Medicines Agency post-authorisation procedural advice for users of the centralised procedure

Notifying a change of marketing status

Human medicines European public assessment report (EPAR): Breyanzi, lisocabtagene maraleucel, Lymphoma, Large B-Cell, Diffuse;Lymphoma, Follicular;Mediastinal Neoplasms, Date of authorisation: 04/04/2022, Revision: 2, Status: Authorised